- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Syn2bio expects cardiomarker trial to be completed within next few months in Europe | 1 | PAP | ||
| Mi | Syn2bio debuts on Warsaw Stock Exchange | 1 | PAP | ||
| 08.04. | Syn2bio to debut on Warsaw Stock Exchange on April 15 | 5 | PAP | ||
| 19.03. | Synektik's EGM approves company's split, followed by spin-off of cardiac biomarker project to Syn2bio | 3 | PAP | ||
| 16.03. | Syn2bio sees partnership agreements as main source of revenue; no share issue planned | 1 | PAP | ||
| SYN2BIO Aktie jetzt für 0€ handeln | |||||
| 12.03. | Polish financial watchdog approves Syn2bio prospectus, debut around April 16 | 1 | PAP | ||
| 17.02. | Synektik medical expects Syn2bio's IPO on WSE around April | 2 | PAP |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 90,55 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,870 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| IMMUNOVANT | 27,350 | 0,00 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,600 | 0,00 % | Recursion-CEO erläutert KI-Strategie zur Beschleunigung der Medikamentenentwicklung | ||
| SIONNA THERAPEUTICS | 45,240 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Third Quarter 2025 Financial Results | Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 24,410 | 0,00 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,330 | 0,00 % | Vir Biotechnology Completes Astellas Deal to Advance Prostate Cancer Immunotherapy | ||
| OLEMA PHARMACEUTICALS | 16,480 | 0,00 % | Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment... ► Artikel lesen | |
| CG ONCOLOGY | 66,36 | 0,00 % | CG Oncology, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 10,750 | 0,00 % | Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns? | ||
| PRAXIS PRECISION MEDICINES | 320,94 | -5,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen | |
| MBX BIOSCIENCES | 33,220 | 0,00 % | Stifel bekräftigt Kaufempfehlung für MBX Biosciences und Kursziel von 50 Dollar | ||
| TYRA BIOSCIENCES | 35,070 | 0,00 % | This Tyra Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | ||
| PHATHOM PHARMACEUTICALS | 12,610 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,320 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
SYN2BIO SA gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYN2BIO SA finden Sie auf Wallstreet Online.